Results 21 to 30 of about 1,231,622 (330)

Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis [PDF]

Frontiers in Pharmacology, 2018
The solute carrier family 26, member 9 (SLC26A9) is an epithelial chloride channel that is expressed in several organs affected in patients with cystic fibrosis (CF) including the lungs, the pancreas, and the intestine. Emerging evidence suggests SLC26A9
Anita Balázs, Anita Balázs, Anita Balázs, Marcus A. Mall, Marcus A. Mall, Marcus A. Mall   +5 more
doaj   +3 more sources

Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del]. [PDF]

Curr Issues Mol Biol, 2022
The presence of complex alleles in the CFTR gene can lead to difficulties in diagnosing cystic fibrosis and cause resistance to therapy with CFTR modulators.
Kondratyeva E, Bulatenko N, Melyanovskaya Y, Efremova A, Zhekaite E, Sherman V, Voronkova A, Asherova I, Polyakov A, Adyan T, Kovalskaia V, Bukharova T, Goldshtein D, Kutsev S.   +13 more
europepmc   +2 more sources

CFTR modulator use in post lung transplant recipients. [PDF]

The Journal of Heart and Lung Transplantation, 2021
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapy has previously been contraindicated in solid organ transplant recipients. This was due to lack of data and concern for interactions with immunosuppressive drug regimens. However,
L. Benninger, C. Trillo, J. Lascano
semanticscholar   +3 more sources

How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored? [PDF]

Am J Respir Crit Care Med, 2022
Ben-Meir E, Grasemann H.
europepmc   +2 more sources

Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment

Journal of Cystic Fibrosis
Edith T. Zemanick, Bonnie W. Ramsey, Dorota Sands, Edward F. McKone, Isabelle Fajac, Jennifer L. Taylor‐Cousar, Marcus Mall, Michael W. Konstan, Nitin Nair, Jesse Zhu, Emilio Arteaga‐Solis, Fredrick Van Goor, Lisa J. McGarry, Valentin Prieto-Centurion, Patrick R. Sosnay, Carmen Bozic, David Waltz, Nicole Mayer-Hamblett   +17 more
openalex   +2 more sources

Review of CFTR modulators 2020 [PDF]

Pediatric Pulmonology, 2021
AbstractCystic fibrosis transmembrane conductance regulator (CFTR) modulators are small molecules that directly impact the CFTR protein, improving the function of the CFTR chloride and bicarbonate channel. Beginning in 2012 with the Food and Drug Administration approval of the first CFTR modulator, ivacaftor, this class of medications has had largely ...
Danielle M. Goetz, Adrienne P. Savant
openaire   +2 more sources

Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis. [PDF]

J Cyst Fibros
Zemanick ET, Emerman I, McCreary M, Mayer-Hamblett N, Warden MN, Odem-Davis K, VanDevanter DR, Ren CL, Young J, Konstan MW, CHEC-SC Study Group.   +10 more
europepmc   +2 more sources

Sinus Disease Grading on Computed Tomography Before and After Modulating Therapy in Adult Patients with Cystic Fibrosis

Journal of the Belgian Society of Radiology, 2022
Objectives: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy effects on respiratory function, pulmonary exacerbations and quality of life have been well documented. However, CFTR modulator therapy effects on sinus disease have
Corrado Tagliati, Stefano Pantano, Giuseppe Lanni, Davide Battista, Matteo Marcucci, Marco Fogante, Giulio Argalia, Enrico Paci, Gabriella Lucidi Pressanti, Mingliang Ying, Pietro Ripani   +10 more
doaj   +1 more source

Autophagy in Idiopathic Pulmonary Fibrosis [PDF]

, 2012
Background: Autophagy is a basic cellular homeostatic process important to cell fate decisions under conditions of stress. Dysregulation of autophagy impacts numerous human diseases including cancer and chronic obstructive lung disease.
An, Chang Hyeok, Cao, Jiaofei, Geyer, Alexander, Haspel, Jeffrey Adam, Lin, Ling, Morse, Danielle, Patel, Avignat Suresh, Rosas, Ivan O.   +7 more
core   +20 more sources

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome

Microbiology Spectrum, 2023
People with cystic fibrosis (pwCF) experience a range of persistent gastrointestinal symptoms throughout life. There is evidence indicating interaction between the microbiota and gut pathophysiology in CF.
Ryan Marsh, Claudio Dos Santos, Liam Hanson, Christabella Ng, Giles Major, Alan R. Smyth, Damian Rivett, Christopher van der Gast   +7 more
doaj   +1 more source